<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37364928</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>03</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2056-5933</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>Jun</Month></PubDate></JournalIssue><Title>RMD open</Title><ISOAbbreviation>RMD Open</ISOAbbreviation></Journal><ArticleTitle>NF-kappa-B essential modulator (NEMO) gene polymorphism in an adult woman with systemic lupus erythematosus and recurrent non-tuberculous mycobacterial disseminated infections.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e003149</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/rmdopen-2023-003149</ELocationID><Abstract><AbstractText>Infections are among the most serious complications in patients with systemic lupus erythematosus (SLE), with bacterial and viral infections being the most common. Non-tuberculous mycobacterial (NTM) infections are quite rare and are typically seen in older patients with SLE with longstanding disease duration treated with corticosteroids. Here, we describe a 39-year-old woman with SLE and an unusual pattern of recurrent NTM disseminated infections. After excluding the presence of autoantibodies against interferon-&#x3b3;, whole exome sequencing revealed a homozygous polymorphism in the NF-kappa-B essential modulator (NEMO) gene. Primary immunodeficiencies should be included in the differential diagnosis of patients with recurrent opportunistic infections, even in those with iatrogenic immunosuppression.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Thomas</LastName><ForeName>Konstantinos</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-7489-7776</Identifier><AffiliationInfo><Affiliation>4th Department of Internal Medicine, University of Athens School of Medicine, Attikon University General Hospital, Chaidari, Attica, Greece costas_thomas@yahoo.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsioulos</LastName><ForeName>Georgios</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>4th Department of Internal Medicine, University of Athens School of Medicine, Attikon University General Hospital, Chaidari, Attica, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kotsogianni</LastName><ForeName>Christina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>4th Department of Internal Medicine, University of Athens School of Medicine, Attikon University General Hospital, Chaidari, Attica, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Banos</LastName><ForeName>Agellos</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Biomedical Research Foundation of the Academy of Athens, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Niemela</LastName><ForeName>Julie E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, National Institutes of Health Clinical Center, Bethesda, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Aristine</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-1182-7375</Identifier><AffiliationInfo><Affiliation>Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DiMaggio</LastName><ForeName>Tom</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holland</LastName><ForeName>Steven</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosenzweig</LastName><ForeName>Sergio D</ForeName><Initials>SD</Initials><AffiliationInfo><Affiliation>Immunology Service, Department of Laboratory Medicine, National Institutes of Health Clinical Center, Bethesda, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tziolos</LastName><ForeName>Nikolaos</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>4th Department of Internal Medicine, University of Athens School of Medicine, Attikon University General Hospital, Chaidari, Attica, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Papadopoulos</LastName><ForeName>Antonios</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>4th Department of Internal Medicine, University of Athens School of Medicine, Attikon University General Hospital, Chaidari, Attica, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lionakis</LastName><ForeName>Michail S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boumpas</LastName><ForeName>Dimitrios T</ForeName><Initials>DT</Initials><Identifier Source="ORCID">0000-0002-9812-4671</Identifier><AffiliationInfo><Affiliation>4th Department of Internal Medicine, University of Athens School of Medicine, Attikon University General Hospital, Chaidari, Attica, Greece.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>RMD Open</MedlineTA><NlmUniqueID>101662038</NlmUniqueID><ISSNLinking>2056-5933</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007165" MajorTopicYN="N">Immunosuppression Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009170" MajorTopicYN="Y">Nontuberculous Mycobacteria</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011110" MajorTopicYN="N">Polymorphism, Genetic</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Infections</Keyword><Keyword MajorTopicYN="N">Inflammation</Keyword><Keyword MajorTopicYN="N">Lupus Erythematosus, Systemic</Keyword><Keyword MajorTopicYN="N">Polymorphism, Genetic</Keyword></KeywordList><CoiStatement>Competing interests: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>3</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>6</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>28</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>27</Day><Hour>1</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>26</Day><Hour>20</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37364928</ArticleId><ArticleId IdType="pmc">PMC10410970</ArticleId><ArticleId IdType="doi">10.1136/rmdopen-2023-003149</ArticleId><ArticleId IdType="pii">rmdopen-2023-003149</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Jung J-Y, Yoon D, Choi Y, et al. . Associated clinical factors for serious infections in patients with systemic lupus erythematosus. Sci Rep 2019;9:9704. 10.1038/s41598-019-46039-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-46039-5</ArticleId><ArticleId IdType="pmc">PMC6609713</ArticleId><ArticleId IdType="pubmed">31273256</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu C-Y, Ko C-H, Wang J-L, et al. . Comparing the burdens of opportunistic infections among patients with systemic rheumatic diseases: a nationally representative cohort study. Arthritis Res Ther 2019;21:211. 10.1186/s13075-019-1997-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-019-1997-5</ArticleId><ArticleId IdType="pmc">PMC6790041</ArticleId><ArticleId IdType="pubmed">31604447</ArticleId></ArticleIdList></Reference><Reference><Citation>Mok MY, Wong SSY, Chan TM, et al. . Non-tuberculous mycobacterial infection in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2007;46:280&#x2013;4. 10.1093/rheumatology/kel206</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kel206</ArticleId><ArticleId IdType="pubmed">16861709</ArticleId></ArticleIdList></Reference><Reference><Citation>CLSI . Susceptibility Testing of Mycobacteria, Nocardiae Other Aerobic Actinomycetes CLSI document M24-A2, 2nd ed. Wayne, PA: Clinical and Laboratory Standards Institute, 2011.</Citation><ArticleIdList><ArticleId IdType="pubmed">31339680</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratnatunga CN, Lutzky VP, Kupz A, et al. . The rise of non-tuberculosis mycobacterial lung disease. Front Immunol 2020;11:303. 10.3389/fimmu.2020.00303</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.00303</ArticleId><ArticleId IdType="pmc">PMC7062685</ArticleId><ArticleId IdType="pubmed">32194556</ArticleId></ArticleIdList></Reference><Reference><Citation>Browne SK, Holland SM. Anticytokine autoantibodies in infectious diseases: pathogenesis and mechanisms. Lancet Infect Dis 2010;10:875&#x2013;85. 10.1016/S1473-3099(10)70196-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(10)70196-1</ArticleId><ArticleId IdType="pubmed">21109174</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel SY, Ding L, Brown MR, et al. . Anti-IFN-gamma autoantibodies in disseminated nontuberculous mycobacterial infections. J Immunol 2005;175:4769&#x2013;76. 10.4049/jimmunol.175.7.4769</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.175.7.4769</ArticleId><ArticleId IdType="pubmed">16177125</ArticleId></ArticleIdList></Reference><Reference><Citation>Kojima H, Aizawa Y, Yanai Y, et al. . An essential role for NF-Kappa B in IL-18-induced IFN-gamma expression in KG-1 cells. J Immunol 1999;162:5063&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">10227974</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin J, Hu H, Li HS, et al. . Noncanonical NF-&#x3ba;B pathway controls the production of type I interferons in antiviral innate immunity. Immunity 2014;40:342&#x2013;54. 10.1016/j.immuni.2014.02.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2014.02.006</ArticleId><ArticleId IdType="pmc">PMC3983709</ArticleId><ArticleId IdType="pubmed">24656046</ArticleId></ArticleIdList></Reference><Reference><Citation>Basagoudanavar SH, Thapa RJ, Nogusa S, et al. . Distinct roles for the NF-&#x3ba;B rela subunit during antiviral innate immune responses. J Virol 2011;85:2599&#x2013;610. 10.1128/JVI.02213-10</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02213-10</ArticleId><ArticleId IdType="pmc">PMC3067974</ArticleId><ArticleId IdType="pubmed">21209118</ArticleId></ArticleIdList></Reference><Reference><Citation>Najjar I, Baran-Marszak F, Le Clorennec C, et al. . Latent membrane protein 1 regulates STAT1 through NF-&#x3ba;B-dependent interferon secretion in Epstein-Barr virus-immortalized B cells. J Virol 2005;79:4936&#x2013;43. 10.1128/JVI.79.8.4936-4943.2005</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.79.8.4936-4943.2005</ArticleId><ArticleId IdType="pmc">PMC1069527</ArticleId><ArticleId IdType="pubmed">15795279</ArticleId></ArticleIdList></Reference><Reference><Citation>Szymanski EP, Leung JM, Fowler CJ, et al. . Pulmonary nontuberculous mycobacterial infection a multisystem, multigenic disease. Am J Respir Crit Care Med 2015;192:618&#x2013;28. 10.1164/rccm.201502-0387OC</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.201502-0387OC</ArticleId><ArticleId IdType="pmc">PMC4595692</ArticleId><ArticleId IdType="pubmed">26038974</ArticleId></ArticleIdList></Reference><Reference><Citation>Honda JR, Alper S, Bai X, et al. . Acquired and genetic host susceptibility factors and microbial pathogenic factors that predispose to nontuberculous mycobacterial infections. Curr Opin Immunol 2018;54:66&#x2013;73. 10.1016/j.coi.2018.06.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coi.2018.06.001</ArticleId><ArticleId IdType="pubmed">29936307</ArticleId></ArticleIdList></Reference><Reference><Citation>Filipe-Santos O, Bustamante J, Haverkamp MH, et al. . X-linked susceptibility to mycobacteria is caused by mutations in NEMO impairing CD40-dependent IL-12 production. J Exp Med 2006;203:1745&#x2013;59. 10.1084/jem.20060085</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20060085</ArticleId><ArticleId IdType="pmc">PMC2118353</ArticleId><ArticleId IdType="pubmed">16818673</ArticleId></ArticleIdList></Reference><Reference><Citation>Aradhya S, Courtois G, Rajkovic A, et al. . Atypical forms of incontinentia pigmenti in male individuals result from mutations of a cytosine tract in exon 10 of NEMO (IKK-gamma). Am J Hum Genet 2001;68:765&#x2013;71. 10.1086/318806</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/318806</ArticleId><ArticleId IdType="pmc">PMC1274488</ArticleId><ArticleId IdType="pubmed">11179023</ArticleId></ArticleIdList></Reference><Reference><Citation>Fusco F, Bardaro T, Fimiani G, et al. . Molecular analysis of the genetic defect in a large cohort of IP patients and identification of novel NEMO mutations interfering with NF-&#x3ba;B activation. Hum Mol Genet 2004;13:1763&#x2013;73. 10.1093/hmg/ddh192</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddh192</ArticleId><ArticleId IdType="pubmed">15229184</ArticleId></ArticleIdList></Reference><Reference><Citation>Gautheron J, Pescatore A, Fusco F, et al. . Identification of a new NEMO/TRAF6 interface affected in incontinentia pigmenti pathology. Hum Mol Genet 2010;19:3138&#x2013;49. 10.1093/hmg/ddq222</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddq222</ArticleId><ArticleId IdType="pubmed">20529958</ArticleId></ArticleIdList></Reference><Reference><Citation>Frans G, van der Werff Ten Bosch J, Moens L, et al. . Functional evaluation of an IKBKG variant suspected to cause immunodeficiency without ectodermal dysplasia. J Clin Immunol 2017;37:801&#x2013;10. 10.1007/s10875-017-0448-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10875-017-0448-9</ArticleId><ArticleId IdType="pubmed">28993958</ArticleId></ArticleIdList></Reference><Reference><Citation>Orange JS, Levy O, Brodeur SR, et al. . Human nuclear factor Kappa B essential modulator mutation can result in immunodeficiency without ectodermal dysplasia. J Allergy Clin Immunol 2004;114:650&#x2013;6. 10.1016/j.jaci.2004.06.052</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2004.06.052</ArticleId><ArticleId IdType="pubmed">15356572</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolitz E, Chamseddin B, Son R, et al. . A novel NEMO/IKBKG mutation identified in a primary immunodeficiency disorder with recurrent atypical mycobacterial infections. JAAD Case Rep 2021;7:33&#x2013;5. 10.1016/j.jdcr.2020.10.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jdcr.2020.10.019</ArticleId><ArticleId IdType="pmc">PMC7727292</ArticleId><ArticleId IdType="pubmed">33318999</ArticleId></ArticleIdList></Reference><Reference><Citation>Keller MD, Petersen M, Ong P, et al. . Hypohidrotic ectodermal dysplasia and immunodeficiency with coincident NEMO and EDA mutations. Front Immunol 2011;2:61. 10.3389/fimmu.2011.00061</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2011.00061</ArticleId><ArticleId IdType="pmc">PMC3341983</ArticleId><ArticleId IdType="pubmed">22566850</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng LE, Kanwar B, Tcheurekdjian H, et al. . Persistent systemic inflammation and atypical enterocolitis in patients with NEMO syndrome. Clin Immunol 2009;132:124&#x2013;31. 10.1016/j.clim.2009.03.514</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2009.03.514</ArticleId><ArticleId IdType="pmc">PMC2800791</ArticleId><ArticleId IdType="pubmed">19375390</ArticleId></ArticleIdList></Reference><Reference><Citation>Piccoli GB, Attini R, Vigotti FN, et al. . NEMO syndrome (incontinentia pigmenti) and systemic lupus erythematosus: a new disease association. Lupus 2012;21:675&#x2013;81. 10.1177/0961203311433140</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203311433140</ArticleId><ArticleId IdType="pubmed">22235006</ArticleId></ArticleIdList></Reference><Reference><Citation>Baldini L, Di Sabatino F, Bodrero E, et al. . NeMO mutations: a rare cause of monogenic Beh&#xe7;et-like disease. Rheumatology (Oxford) 2021;60:e92&#x2013;4. 10.1093/rheumatology/keaa505</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keaa505</ArticleId><ArticleId IdType="pubmed">32954429</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee Y, Wessel AW, Xu J, et al. . Genetically programmed alternative splicing of NEMO mediates an autoinflammatory disease phenotype. J Clin Invest 2022;132:e128808. 10.1172/JCI128808</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI128808</ArticleId><ArticleId IdType="pmc">PMC8920334</ArticleId><ArticleId IdType="pubmed">35289316</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>